Informacja

Drogi użytkowniku, aplikacja do prawidłowego działania wymaga obsługi JavaScript. Proszę włącz obsługę JavaScript w Twojej przeglądarce.

English (EN)·Polski (PL)·Ukraiński (UK)
Przejdź do strony domowej biblioteki Uniwersytet Ekonomiczny we Wrocławiu Link otwiera się w nowym oknie Logo biblioteki Prolib Integro - strona głównaUniwersytet Ekonomiczny we Wrocławiu

Wyszukujesz frazę ""Infliximab"" wg kryterium: Temat

  Lista filtrów
Wyrównaj
Wyświetlanie 1-20 z 19027
Tytuł:
Exploring treatment of inflammatory bowel disease with infliximab in the Middle East and Northern Africa: An analysis of the HARIR observational cohort study.
Autorzy:
Alharbi O; Gastroenterology Section, King Khalid University Hospital, College of Medicine, King Saud University, Riyadh, Saudi Arabia.
Hamed W; Ain Shams University Hospital, Department of Tropical Medicine, Cairo, Egypt.
Salem O; Osama Ebada GI Center, Department of Internal Medicine, Alexandria, Egypt.
Taylor C; Janssen, Medical Affairs, Dubai, United Arab Emirates.
Besar A; Janssen, Medical Affairs, Dubai, United Arab Emirates.
Sharaf M; Janssen, Medical Affairs, Jeddah, Saudi Arabia.
Pokaż więcej
Źródło:
Saudi journal of gastroenterology : official journal of the Saudi Gastroenterology Association [Saudi J Gastroenterol] 2023 May-Jun; Vol. 29 (3), pp. 164-170.
Typ publikacji:
Observational Study; Multicenter Study; Journal Article
MeSH Terms:
Biological Products*
Colitis, Ulcerative*/drug therapy
Colitis, Ulcerative*/epidemiology
Inflammatory Bowel Diseases*/drug therapy
Inflammatory Bowel Diseases*/epidemiology
Infliximab*/therapeutic use
Antibodies, Monoclonal*/therapeutic use
Gastrointestinal Agents*/therapeutic use
Humans ; Africa, Northern ; Cohort Studies ; Crohn Disease/drug therapy ; Crohn Disease/epidemiology ; Middle East/epidemiology ; Prospective Studies ; Treatment Outcome
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknieSzczegóły
Tytuł:
Predictive biomarkers for anti-TNF alpha therapy in IBD patients.
Autorzy:
Kumar M; Research Department, Sidra Medicine, Doha, Qatar.
Murugesan S; Research Department, Sidra Medicine, Doha, Qatar.
Ibrahim N; Division of Gastroenterology, Hepatology and Nutrition, Sidra Medicine, Doha, Qatar.
Elawad M; Division of Gastroenterology, Hepatology and Nutrition, Sidra Medicine, Doha, Qatar.
Al Khodor S; Research Department, Sidra Medicine, Doha, Qatar. .
Pokaż więcej
Źródło:
Journal of translational medicine [J Transl Med] 2024 Mar 16; Vol. 22 (1), pp. 284. Date of Electronic Publication: 2024 Mar 16.
Typ publikacji:
Journal Article; Review
MeSH Terms:
Inflammatory Bowel Diseases*/drug therapy
Colitis, Ulcerative*/drug therapy
Adult ; Humans ; Infliximab/therapeutic use ; Tumor Necrosis Factor Inhibitors/therapeutic use ; Tumor Necrosis Factor-alpha/therapeutic use ; Biomarkers
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły
Tytuł:
Efficacy and safety of Infliximab in systemic sarcoidosis according to GenPhenReSa organ-involvement phenotype: a retrospective study of 55 patients.
Autorzy:
Rivière E; Internal Medicine and Infectious Diseases unit, Haut-Leveque Hospital, University Hospital Centre of Bordeaux, F33604, Pessac Cedex, France. .; INSERM U1034, Bordeaux University, F33604, Pessac Cedex, France. .
Jourde W; Internal Medicine and Infectious Diseases unit, Haut-Leveque Hospital, University Hospital Centre of Bordeaux, F33604, Pessac Cedex, France.
Gensous N; Department of Internal Medicine and Clinical Immunology, Saint Andre Hospital, University Hospital Centre of Bordeaux, F33000, Bordeaux, France.; ImmunoconcEpT; FHU ACRONIM, UMR CNRS 5164, Bordeaux University, F33000, Bordeaux, France.
Demant X; Respiratory Diseases unit, Haut-Leveque Hospital, University Hospital Centre of Bordeaux, CIC 1401, F33604, Pessac Cedex, France.
Ribeiro E; ImmunoconcEpT; FHU ACRONIM, UMR CNRS 5164, Bordeaux University, F33000, Bordeaux, France.
Duffau P; Department of Internal Medicine and Clinical Immunology, Saint Andre Hospital, University Hospital Centre of Bordeaux, F33000, Bordeaux, France.; ImmunoconcEpT; FHU ACRONIM, UMR CNRS 5164, Bordeaux University, F33000, Bordeaux, France.
Mercié P; Department of Internal Medicine and Clinical Immunology, Saint Andre Hospital, University Hospital Centre of Bordeaux, F33000, Bordeaux, France.; Univ. Bordeaux, INSERM, BRIC, U1312, F33000, Bordeaux, France.
Viallard JF; Internal Medicine and Infectious Diseases unit, Haut-Leveque Hospital, University Hospital Centre of Bordeaux, F33604, Pessac Cedex, France.; INSERM U1034, Bordeaux University, F33604, Pessac Cedex, France.
Lazaro E; Internal Medicine and Infectious Diseases unit, Haut-Leveque Hospital, University Hospital Centre of Bordeaux, F33604, Pessac Cedex, France.; ImmunoconcEpT; FHU ACRONIM, UMR CNRS 5164, Bordeaux University, F33000, Bordeaux, France.
Pokaż więcej
Źródło:
Respiratory research [Respir Res] 2024 Mar 14; Vol. 25 (1), pp. 124. Date of Electronic Publication: 2024 Mar 14.
Typ publikacji:
Journal Article
MeSH Terms:
Sarcoidosis*/diagnosis
Sarcoidosis*/drug therapy
Humans ; Infliximab/adverse effects ; Retrospective Studies ; Treatment Outcome ; Phenotype
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły
Tytuł:
90K/Mac-2 BP Is a New Predictive Biomarker of Response to Infliximab Therapy in IBD Patients.
Autorzy:
Pesole PL; National Institute of Gastroenterology-IRCCS, 'Saverio de Bellis', 70013 Castellana Grotte, Italy.
Liso M; National Institute of Gastroenterology-IRCCS, 'Saverio de Bellis', 70013 Castellana Grotte, Italy.
Donghia R; National Institute of Gastroenterology-IRCCS, 'Saverio de Bellis', 70013 Castellana Grotte, Italy.
Guerra V; National Institute of Gastroenterology-IRCCS, 'Saverio de Bellis', 70013 Castellana Grotte, Italy.
Lippolis A; National Institute of Gastroenterology-IRCCS, 'Saverio de Bellis', 70013 Castellana Grotte, Italy.
Mastronardi M; National Institute of Gastroenterology-IRCCS, 'Saverio de Bellis', 70013 Castellana Grotte, Italy.
Iacovazzi PA; National Institute of Gastroenterology-IRCCS, 'Saverio de Bellis', 70013 Castellana Grotte, Italy.
Pokaż więcej
Źródło:
International journal of molecular sciences [Int J Mol Sci] 2023 Feb 16; Vol. 24 (4). Date of Electronic Publication: 2023 Feb 16.
Typ publikacji:
Observational Study; Journal Article
MeSH Terms:
Biological Products*/therapeutic use
Colitis, Ulcerative*/drug therapy
Crohn Disease*/drug therapy
Infliximab*/therapeutic use
Humans ; Biomarkers ; C-Reactive Protein/metabolism ; Cytokines/therapeutic use
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły
Tytuł:
Absolute monocyte counts could predict disease activity and secondary loss of response of patients with Crohn's disease treated with anti-TNF-α drug.
Autorzy:
Hu J; Department of Gastroenterology, The Second Xiangya Hospital, Central South University, Changsha, Hunan, China.; Research Center of Digestive Disease, The Second Xiangya Hospital, Central South University, Changsha, Hunan, China.
Huang Y; Department of Gastroenterology, The Second Xiangya Hospital, Central South University, Changsha, Hunan, China.; Research Center of Digestive Disease, The Second Xiangya Hospital, Central South University, Changsha, Hunan, China.
Jia R; Department of Gastroenterology, The Second Xiangya Hospital, Central South University, Changsha, Hunan, China.; Research Center of Digestive Disease, The Second Xiangya Hospital, Central South University, Changsha, Hunan, China.
Wang X; Department of Gastroenterology, The Second Xiangya Hospital, Central South University, Changsha, Hunan, China.; Research Center of Digestive Disease, The Second Xiangya Hospital, Central South University, Changsha, Hunan, China.
Wang Y; Department of Gastroenterology, The Second Xiangya Hospital, Central South University, Changsha, Hunan, China.; Research Center of Digestive Disease, The Second Xiangya Hospital, Central South University, Changsha, Hunan, China.
Pokaż więcej
Źródło:
PloS one [PLoS One] 2024 Apr 10; Vol. 19 (4), pp. e0301797. Date of Electronic Publication: 2024 Apr 10 (Print Publication: 2024).
Typ publikacji:
Journal Article
MeSH Terms:
Crohn Disease*/drug therapy
Crohn Disease*/diagnosis
Biological Products*/therapeutic use
Humans ; Tumor Necrosis Factor-alpha/therapeutic use ; Tumor Necrosis Factor Inhibitors/therapeutic use ; Monocytes ; Infliximab/therapeutic use ; Adalimumab/therapeutic use
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły
Tytuł:
Analysis of the risk of future gastrointestinal surgery in Crohn's disease with stricture.
Autorzy:
Zeng W; Department of Scientific Research and Teaching, Central Hospital of Shaoyang, Shaoyan, China.
Chen Y; Department of Oncology, Central Hospital of Shaoyang, Shaoyan, China.
Yin B; Department of Scientific Research and Teaching, Central Hospital of Shaoyang, Shaoyan, China.
Wen X; Department of Scientific Research and Teaching, Central Hospital of Shaoyang, Shaoyan, China.; Graduate School, University of South China, China.
Xiao J; Graduate School, University of South China, China.; Department of Hepatobiliary Surgery, Central Hospital of Shaoyang, Shaoyan, China.
Luo L; Department of Oncology, Central Hospital of Shaoyang, Shaoyan, China.; Graduate School, University of South China, China.
Tang H; Department of Neurology and Stroke Center, Central Hospital of Shaoyang, Shaoyan, China.
Zheng H; Department of Hepatobiliary Surgery, Central Hospital of Shaoyang, Shaoyan, China.
Pokaż więcej
Źródło:
Saudi journal of gastroenterology : official journal of the Saudi Gastroenterology Association [Saudi J Gastroenterol] 2024 Mar 01; Vol. 30 (2), pp. 108-113. Date of Electronic Publication: 2023 Oct 25.
Typ publikacji:
Journal Article
MeSH Terms:
Crohn Disease*/complications
Crohn Disease*/drug therapy
Crohn Disease*/surgery
Digestive System Surgical Procedures*
Humans ; Constriction, Pathologic/surgery ; Retrospective Studies ; Infliximab/therapeutic use
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły
Tytuł:
Tumor necrosis factor inhibitors and janus kinase inhibitors in the treatment of cicatricial alopecia: A systematic review.
Autorzy:
Hajizadeh N; School of Medicine, Iran University of Medical Sciences, Tehran, Iran.; Rasool Akram Medical Complex Clinical Research Development Center (RCRDC), Iran University of Medical Sciences, Tehran, Iran.
Heidari A; Faculty of Medicine, Tehran Medical Sciences, Islamic Azad University, Tehran, Iran.
Sadeghi S; Rasool Akram Medical Complex Clinical Research Development Center (RCRDC), Iran University of Medical Sciences, Tehran, Iran.; Department of Medicine, New York Health System, South Brooklyn Hospital, New York, NY, United States of America.
Goodarzi A; Rasool Akram Medical Complex Clinical Research Development Center (RCRDC), Iran University of Medical Sciences, Tehran, Iran.; Department of Dermatology, Faculty of Dermatology, Rasool Akram Medical Complex Clinical Research Development Center (RCRDC), School of Medicine, Iran University of Medical Sciences, Tehran, Iran.
Pokaż więcej
Źródło:
PloS one [PLoS One] 2024 Feb 09; Vol. 19 (2), pp. e0293433. Date of Electronic Publication: 2024 Feb 09 (Print Publication: 2024).
Typ publikacji:
Systematic Review; Journal Article
MeSH Terms:
Janus Kinase Inhibitors*/adverse effects
Humans ; Adalimumab/therapeutic use ; Tumor Necrosis Factor Inhibitors ; Infliximab ; Antibodies, Monoclonal, Humanized/therapeutic use ; Alopecia/drug therapy ; Tumor Necrosis Factor-alpha
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły
Tytuł:
Infliximab in neurosarcoidosis: a systematic review and meta-analysis.
Autorzy:
Chaiyanarm S; Faculty of Medicine Siriraj Hospital, Mahidol University, Bangkok, 10700, Thailand.
Satiraphan P; Faculty of Medicine Siriraj Hospital, Mahidol University, Bangkok, 10700, Thailand.
Apiraksattaykul N; Siriraj Neuroimmunology Center, Division of Neurology, Department of Medicine, Faculty of Medicine Siriraj Hospital, Mahidol University, Bangkok, 10700, Thailand.
Jitprapaikulsan J; Siriraj Neuroimmunology Center, Division of Neurology, Department of Medicine, Faculty of Medicine Siriraj Hospital, Mahidol University, Bangkok, 10700, Thailand.; Division of Neurology, Department of Medicine, Faculty of Medicine Siriraj Hospital, Mahidol University, Bangkok, 10700, Thailand.
Owattanapanich W; Division of Hematology, Department of Medicine, Faculty of Medicine Siriraj Hospital, Mahidol University, Bangkok, 10700, Thailand.
Rungjirajittranon T; Division of Hematology, Department of Medicine, Faculty of Medicine Siriraj Hospital, Mahidol University, Bangkok, 10700, Thailand.
Nanthasi W; Division of Neurology, Department of Medicine, Faculty of Medicine Siriraj Hospital, Mahidol University, Bangkok, 10700, Thailand.
Pokaż więcej
Źródło:
Annals of clinical and translational neurology [Ann Clin Transl Neurol] 2024 Feb; Vol. 11 (2), pp. 466-476. Date of Electronic Publication: 2023 Dec 12.
Typ publikacji:
Meta-Analysis; Systematic Review; Journal Article
MeSH Terms:
Immunosuppressive Agents*/therapeutic use
Adrenal Cortex Hormones*
Central Nervous System Diseases*
Sarcoidosis*
Humans ; Infliximab/adverse effects ; Recurrence
SCR Disease Name:
Neurosarcoidosis
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły
Tytuł:
Local injection of infliximab into calcinosis lesions in patients with juvenile dermatomyositis (JDM): a clinical trial.
Autorzy:
Shiari R; Research Institute for Children's Health, Shahid Beheshti University of Medical Sciences, Tehran, Iran.
Khalili M; Research Institute for Children's Health, Shahid Beheshti University of Medical Sciences, Tehran, Iran.
Zeinali V; Research Institute for Children's Health, Shahid Beheshti University of Medical Sciences, Tehran, Iran.
Shashaani N; Research Institute for Children's Health, Shahid Beheshti University of Medical Sciences, Tehran, Iran.
Samami M; Dental Sciences Research Center, Department of Oral and Maxillofacial Medicine, School of Dentistry, Guilan University of Medical Sciences, Rasht, Iran.
Moghaddamemami FH; Department of Pediatric Rheumatology, School of Medicine, Guilan University of Medical Sciences, Rasht, Iran. .
Pokaż więcej
Źródło:
Pediatric rheumatology online journal [Pediatr Rheumatol Online J] 2024 Jan 02; Vol. 22 (1), pp. 2. Date of Electronic Publication: 2024 Jan 02.
Typ publikacji:
Journal Article
MeSH Terms:
Dermatomyositis*/complications
Dermatomyositis*/drug therapy
Dermatomyositis*/diagnosis
Calcinosis*/diagnostic imaging
Calcinosis*/drug therapy
Calcinosis*/etiology
Humans ; Infliximab/therapeutic use ; Skin ; Injections
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły
Tytuł:
Timing of Live Attenuated Vaccination in Infants Exposed to Infliximab or Adalimumab in Utero: A Prospective Cohort Study in 107 Children.
Autorzy:
Liu Z; Clinical Pharmacology, School of Medicine and Public Health, University of Newcastle, Hunter Medical Research Institute, Kookaburra Circuit, Australia.; Clinical Pharmacology, Department of Medicine, The Royal Children's Hospital Melbourne, Australia.; Centre for Medicine Use and Safety, Faculty of Pharmacy and Pharmaceutical Sciences, Monash University, Parkville, Victoria, Australia.
Julsgaard M; Department of Hepatology and Gastroenterology, Aarhus University Hospital, Aarhus, Denmark.; Institute of Clinical Medicine, Aarhus University, Aarhus, Denmark.; Department of Gastroenterology, St Vincent's Hospital, and University of Melbourne, Melbourne, Australia.
Zhu X; Department of Clinical Pharmacy and Pharmacy Administration, School of Pharmacy, Fudan University, China.; School of Pharmacy, University of Otago, Dunedin, New Zealand.
Martin J; Clinical Pharmacology, School of Medicine and Public Health, University of Newcastle, Hunter Medical Research Institute, Kookaburra Circuit, Australia.
Barclay ML; Departments of Gastroenterology & Clinical Pharmacology, Christchurch Hospital, Christchurch, New Zealand.
Cranswick N; Clinical Pharmacology, Department of Medicine, The Royal Children's Hospital Melbourne, Australia.
Gibson PR; Department of Gastroenterology, Alfred Hospital, and Monash University, Melbourne, VIC, Australia.
Gearry RB; Department of Medicine, University of Otago, Christchurch, New Zealand.
van der Giessen J; Department of Gastroenterology and Hepatology, Erasmus University Medical Center Rotterdam, Rotterdam, The Netherlands.
Connor SJ; Department of Gastroenterology, Liverpool Hospital, Sydney.; South Western Sydney Clinical, University of NSW Sydney.; Ingham Institute of Applied Medical Research, Sydney, Australia.
Rosella O; Department of Gastroenterology, Alfred Hospital, and Monash University, Melbourne, VIC, Australia.
Grosen A; Department of Hepatology and Gastroenterology, Aarhus University Hospital, Aarhus, Denmark.
Toong C; South Western Sydney Clinical, University of NSW Sydney.; Sydney South West Pathology Service, Liverpool Hospital, University of NSW, Sydney, Australia.
Flanagan E; Department of Gastroenterology, St Vincent's Hospital, and University of Melbourne, Melbourne, Australia.
Wieringa JW; Department of Pediatrics, Haaglanden Medical Center, the Hague, The Netherlands.; Department of Pediatrics, Division of Paediatric Infectious Diseases and Immunology, Erasmus MC University Medical Centre-Sophia Children's Hospital, Rotterdam, The Netherlands.
Janneke van der Woude C; Department of Gastroenterology and Hepatology, Erasmus University Medical Center Rotterdam, Rotterdam, The Netherlands.
Bell SJ; Department of Gastroenterology, St Vincent's Hospital, and University of Melbourne, Melbourne, Australia.; Department of Gastroenterology, Monash Health, and School of Clinical Sciences Monash University, Melbourne, VIC, Australia.
Pokaż więcej
Corporate Authors:
CARINA Study Group
Źródło:
Journal of Crohn's & colitis [J Crohns Colitis] 2022 Dec 05; Vol. 16 (12), pp. 1835-1844.
Typ publikacji:
Journal Article
MeSH Terms:
Adalimumab*/therapeutic use
Inflammatory Bowel Diseases*/drug therapy
Infliximab*/therapeutic use
Vaccines, Attenuated*/administration & dosage
Child ; Female ; Humans ; Infant ; Infant, Newborn ; Pregnancy ; Bayes Theorem ; Prospective Studies ; Tumor Necrosis Factor Inhibitors/therapeutic use ; Vaccination ; Maternal Exposure
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły
Tytuł:
Long lasting response to anti-tumor necrosis factor α agents in psoriasis: A real life experience.
Autorzy:
Musumeci ML; Dermatology Clinic, University of Catania, Catania, Italy.
Trecarichi AC; Dermatology Clinic, University of Catania, Catania, Italy.
Caruso G; Dermatology Clinic, University of Catania, Catania, Italy.
Aleo A; Dermatology Clinic, University of Catania, Catania, Italy.
Platania H; Dermatology Clinic, University of Catania, Catania, Italy.
Micali G; Dermatology Clinic, University of Catania, Catania, Italy.
Pokaż więcej
Źródło:
Dermatologic therapy [Dermatol Ther] 2022 Dec; Vol. 35 (12), pp. e15956. Date of Electronic Publication: 2022 Nov 01.
Typ publikacji:
Journal Article
MeSH Terms:
Adalimumab*/therapeutic use
Etanercept*/therapeutic use
Infliximab*/therapeutic use
Psoriasis*/diagnosis
Psoriasis*/drug therapy
Tumor Necrosis Factor Inhibitors*/therapeutic use
Humans ; Immunoglobulin G ; Necrosis/drug therapy ; Receptors, Tumor Necrosis Factor/therapeutic use
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły
Tytuł:
Multi-model averaging improves the performance of model-guided infliximab dosing in patients with inflammatory bowel diseases.
Autorzy:
Kantasiripitak W; Department of Pharmaceutical and Pharmacological Sciences, University of Leuven, Leuven, Belgium.
Outtier A; Department of Gastroenterology and Hepatology, University Hospitals Leuven, Leuven, Belgium.; Department of Chronic Diseases and Metabolism, University of Leuven, Leuven, Belgium.
Wicha SG; Department of Clinical Pharmacy, Institute of Pharmacy, University of Hamburg, Hamburg, Germany.
Kensert A; Department of Pharmaceutical and Pharmacological Sciences, University of Leuven, Leuven, Belgium.; Department of Chemical Engineering, Vrije Universiteit Brussels, Brussels, Belgium.
Wang Z; Department of Pharmaceutical and Pharmacological Sciences, University of Leuven, Leuven, Belgium.
Sabino J; Department of Gastroenterology and Hepatology, University Hospitals Leuven, Leuven, Belgium.; Department of Chronic Diseases and Metabolism, University of Leuven, Leuven, Belgium.
Vermeire S; Department of Gastroenterology and Hepatology, University Hospitals Leuven, Leuven, Belgium.; Department of Chronic Diseases and Metabolism, University of Leuven, Leuven, Belgium.
Thomas D; Department of Pharmaceutical and Pharmacological Sciences, University of Leuven, Leuven, Belgium.
Ferrante M; Department of Gastroenterology and Hepatology, University Hospitals Leuven, Leuven, Belgium.; Department of Chronic Diseases and Metabolism, University of Leuven, Leuven, Belgium.
Dreesen E; Department of Pharmaceutical and Pharmacological Sciences, University of Leuven, Leuven, Belgium.
Pokaż więcej
Źródło:
CPT: pharmacometrics & systems pharmacology [CPT Pharmacometrics Syst Pharmacol] 2022 Aug; Vol. 11 (8), pp. 1045-1059. Date of Electronic Publication: 2022 Jun 15.
Typ publikacji:
Clinical Study; Journal Article; Research Support, Non-U.S. Gov't
MeSH Terms:
Inflammatory Bowel Diseases*/drug therapy
Infliximab*/pharmacokinetics
Infliximab*/therapeutic use
Colitis, Ulcerative/drug therapy ; Gastrointestinal Agents ; Humans ; Prospective Studies
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły
Tytuł:
Safety, Efficacy and Persistence of Advanced Therapies in Inflammatory Bowel Disease: Results from ORIGINS. A Retrospective Observational Study.
Autorzy:
Mateescu RB; Gastroenterology Department, Colentina Clinical Hospital, Bucharest, Romania. . .
Gheorghe C; Gastroenterology and Hepatology Center, Fundeni Clinical Institute,Bucharest, Romania. .
Trifan AV; Gastroenterology Department, St. Spiridon Emergency Clinical County Hospital, Iasi, Romania. .
Saftoiu A; Gastroenterology Department, Elias Emergency Hospital, Bucharest, Romania. .
Seicean A; Gastroenterology Department, Prof. Dr. Octavian Fodor Gastroenterology Institute, Cluj-Napoca, Romania. .
Diculescu MM; Gastroenterology and Hepatology Center, Fundeni Clinical Institute,Bucharest, Romania. .
Banciu C; Gastroenterology Department, Victor Babes University of Medicine and Pharmacy, Timisoara, Romania. .
Gheorghe LS; Gastroenterology and Hepatology Center, Fundeni Clinical Institute,Bucharest, Romania. .
Busuioc B; Gastroenterology Department, Ion Cantacuzino Clinical Hospital, Bucharest, Romania. .
Goldis A; Gastroenterology Department, Victor Babes University of Medicine and Pharmacy, Timisoara, Romania. .
Dobru D; Gastroenterology Department , University of Medicine , Science and Tehnology G.E.Palade Targu-Mures. .
Fratila O; Third Internal Medicine Department, University of Oradea, Romania. .
Eugen D; Gastroenterology Department, Emergency Clinical County Hospital, Constanta, Romania. .
Bataga S; Gastroenterology Department, Emergency Clinical County Hospital, Targu-Mures, Romania. .
Constantinescu G; Gastroenterology Department ,Emergency Hospital, Bucharest, Romania. .
Gheonea D; Gastroenterology Department, University of Medicine and Pharmacy of Craiova. .
Tantau A; Internal Medicine and Gastroenterology Department, Iuliu-Hatieganu University of Medicine and Pharmacy, Cluj- Napoca, Romania. .
Jinga M; Internal Medicine and Gastroenterology Department, Dr Carol Davila Central University Emergency Military Hospital, Bucharest, Romania. .
Brisc C; Gastroenterology Department, Emergency Clinical County Hospital, Oradea, Romania. .
Cijevschi Prelipcean C; Gastroenterology Department, St. Spiridon Emergency Clinical County Hospital, Iasi, Romania. .
Chira R; Gastroenterology Department, Emergency Clinical County Hospital, Cluj-Napoca, Romania. .
Fierbințeanu-Braticevici C; Gastroenterology Department, Emergency University Hospital Bucharest, Romania. .
Dumitrascu D; Second Department of Internal Medicine, Iuliu Hatieganu University of Medicine and Pharmacy Cluj-Napoca, Cluj-Napoca, Romania. .
State M; Gastroenterology Department, Colentina Clinical Hospital, Bucharest, Romania. .
Voiosu T; Gastroenterology Department, Colentina Clinical Hospital, Bucharest, Romania. .
Negreanu L; Gastroenterology Department, Emergency University Hospital Bucharest, Romania. negreanu_.
Pokaż więcej
Źródło:
Journal of gastrointestinal and liver diseases : JGLD [J Gastrointestin Liver Dis] 2023 Dec 22; Vol. 32 (4), pp. 444-451. Date of Electronic Publication: 2023 Dec 22.
Typ publikacji:
Observational Study; Journal Article
MeSH Terms:
Inflammatory Bowel Diseases*/drug therapy
Colitis, Ulcerative*/diagnosis
Colitis, Ulcerative*/drug therapy
Biological Products*/adverse effects
Adult ; Humans ; Infliximab/adverse effects ; Adalimumab/adverse effects ; Retrospective Studies ; Ustekinumab/adverse effects ; Tumor Necrosis Factor Inhibitors ; Treatment Outcome
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknieSzczegóły
Tytuł:
Effectiveness and safety of adalimumab in patients with intestinal Behçet's disease: a real-world prospective observational study in South Korea.
Autorzy:
Yu J; Department of Internal Medicine, Institute of Gastroenterology, Yonsei University College of Medicine, 50-1 Yonsei-ro, Seodaemun-gu, Seoul, 03722, Korea.
Shin SJ; Department of Gastroenterology, Ajou University School of Medicine, Suwon, Korea.
Park YJ; Division of Rheumatology, Department of Internal Medicine, St. Vincent's Hospital, The Catholic University of Korea, Suwon, South Korea.
Kim HW; Department of Internal Medicine, Pusan National University Yangsan Hospital, Yangsan, South Korea.
Lee BI; Division of Gastroenterology, Department of Internal Medicine, Seoul St. Mary's Hospital, College of Medicine, The Catholic University of Korea, Seoul, Korea.
Ye BD; Department of Gastroenterology and Inflammatory Bowel Disease Center, Asan Medical Center, University of Ulsan College of Medicine, Seoul, South Korea.
Kim GT; Department of Internal Medicine, Kosin University College of Medicine, Busan, Korea.
Kim SK; Department of Internal Medicine, Kyungpook National University Hospital, Daegu, Korea.
Kim JS; Department of Internal Medicine and Liver Research Institute, Seoul National University College of Medicine, Seoul, Korea.
Kim YH; Departments of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea.
Jeong S; AbbVie Ltd, Seoul, Republic of Korea.
Cheon JH; Department of Internal Medicine, Institute of Gastroenterology, Yonsei University College of Medicine, 50-1 Yonsei-ro, Seodaemun-gu, Seoul, 03722, Korea. .
Pokaż więcej
Źródło:
BMC gastroenterology [BMC Gastroenterol] 2023 Dec 19; Vol. 23 (1), pp. 449. Date of Electronic Publication: 2023 Dec 19.
Typ publikacji:
Observational Study; Multicenter Study; Journal Article
MeSH Terms:
Behcet Syndrome*/complications
Behcet Syndrome*/drug therapy
Intestinal Diseases*/drug therapy
Intestinal Diseases*/chemically induced
Humans ; Adalimumab/adverse effects ; Intestines ; Infliximab
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły
Tytuł:
Real-world outcomes following switching from anti-TNF reference products to biosimilars for the treatment of psoriasis.
Autorzy:
Ruda RC; Center for Dermatology Research, Department of Dermatology, Wake Forest School of Medicine, Winston-Salem, NC, USA.
Kelly KA; Center for Dermatology Research, Department of Dermatology, Wake Forest School of Medicine, Winston-Salem, NC, USA.
Feldman SR; Center for Dermatology Research, Department of Dermatology, Wake Forest School of Medicine, Winston-Salem, NC, USA.; Department of Pathology, Wake Forest School of Medicine, Winston-Salem, NC, USA.; Department of Social Sciences & Health Policy, Wake Forest School of Medicine, Winston-Salem, NC, USA.; Department of Dermatology, University of Southern Denmark, Odense, Denmark.
Pokaż więcej
Źródło:
The Journal of dermatological treatment [J Dermatolog Treat] 2023 Dec; Vol. 34 (1), pp. 2140569.
Typ publikacji:
Journal Article; Review
MeSH Terms:
Biosimilar Pharmaceuticals*/therapeutic use
Psoriasis*/drug therapy
Humans ; Infliximab/therapeutic use ; Etanercept/therapeutic use ; Adalimumab/therapeutic use ; Biological Factors/therapeutic use ; Tumor Necrosis Factor Inhibitors/therapeutic use
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły
Tytuł:
Real-world retention rates of biologics in patients with rheumatoid arthritis.
Autorzy:
Takami K; Department of Orthopaedic Surgery, Nippon Life Hospital, 2-1-54 Enokojima, Nishi-ku, Osaka, 550-0006, Japan. .; Department of Rheumatology, Japan Community Healthcare Organization Osaka Hospital, Osaka, Japan. .
Tsuji S; Department of Orthopaedic Surgery, Nippon Life Hospital, 2-1-54 Enokojima, Nishi-ku, Osaka, 550-0006, Japan.
Pokaż więcej
Źródło:
Scientific reports [Sci Rep] 2023 Dec 01; Vol. 13 (1), pp. 21170. Date of Electronic Publication: 2023 Dec 01.
Typ publikacji:
Journal Article
MeSH Terms:
Antirheumatic Agents*/therapeutic use
Biological Products*/therapeutic use
Arthritis, Rheumatoid*/drug therapy
Humans ; Treatment Outcome ; Etanercept/therapeutic use ; Adalimumab/therapeutic use ; Infliximab/therapeutic use ; Abatacept/therapeutic use
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknieSzczegóły
Tytuł:
Upadacitinib as a Rescue Therapy in Acute Severe Ulcerative Colitis: A Case Report and Review of the Literature.
Autorzy:
Ali NM; Department of Medicine, Mubarak AL-Kabeer Hospital, Haya Al-Habib Gastroenterology Center, Jabriya, Kuwait.
Shehab MA; Department of Medicine, Mubarak AL-Kabeer Hospital, Haya Al-Habib Gastroenterology Center, Jabriya, Kuwait.
Pokaż więcej
Źródło:
The American journal of case reports [Am J Case Rep] 2023 Nov 06; Vol. 24, pp. e940966. Date of Electronic Publication: 2023 Nov 06.
Typ publikacji:
Review; Case Reports; Journal Article
MeSH Terms:
Colitis, Ulcerative*/drug therapy
Colitis, Ulcerative*/surgery
Adult ; Female ; Humans ; Adolescent ; Infliximab/therapeutic use ; Heterocyclic Compounds, 3-Ring/therapeutic use ; Mesalamine ; Steroids/therapeutic use ; Treatment Outcome
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknieSzczegóły
Tytuł:
Sarcopenia assessed by computed tomography or magnetic resonance imaging is associated with the loss of response to biologic therapies in adult patients with Crohn's disease.
Autorzy:
Liu J; Department of Radiology, Funan County People's Hospital, Fuyang, Anhui, China.; Department of Radiology, The Affiliated Hospital of Nanjing University of Chinese Medicine, Nanjing, China.
Tang H; Department of Radiology, The Affiliated Hospital of Nanjing University of Chinese Medicine, Nanjing, China.
Lin T; Department of Radiology, The Affiliated Hospital of Nanjing University of Chinese Medicine, Nanjing, China.
Wang J; Department of Radiology, The Affiliated Hospital of Nanjing University of Chinese Medicine, Nanjing, China.
Cui W; Department of Radiology, The Affiliated Hospital of Nanjing University of Chinese Medicine, Nanjing, China.
Xie C; Center of Musculoskeletal Research, University of Rochester School of Medicine, Rochester, New York, USA.
Wang Z; Department of Radiology, The Affiliated Hospital of Nanjing University of Chinese Medicine, Nanjing, China.
Chen Y; Department of Colon and Rectum Surgery, The Affiliated Hospital of Nanjing University of Chinese Medicine, Nanjing, China.
Chen X; Department of Radiology, The Affiliated Hospital of Nanjing University of Chinese Medicine, Nanjing, China.
Pokaż więcej
Źródło:
Clinical and translational science [Clin Transl Sci] 2023 Nov; Vol. 16 (11), pp. 2209-2221. Date of Electronic Publication: 2023 Sep 05.
Typ publikacji:
Journal Article; Research Support, Non-U.S. Gov't
MeSH Terms:
Crohn Disease*/complications
Crohn Disease*/diagnostic imaging
Crohn Disease*/drug therapy
Sarcopenia*/diagnostic imaging
Sarcopenia*/epidemiology
Sarcopenia*/etiology
Humans ; Adult ; Infliximab/adverse effects ; Retrospective Studies ; Biological Therapy ; Biological Factors ; Magnetic Resonance Imaging ; Tomography
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły
Tytuł:
Long-term safety and efficacy of anti-tumor necrosis factor-alpha biosimilar agents in the treatment of psoriasis: a single center study.
Autorzy:
Ricceri F; Department of Health Sciences, Section of Dermatology, University of Florence, Florence, Italy.
Rosi E; Department of Health Sciences, Section of Dermatology, University of Florence, Florence, Italy.
Di Cesare A; Department of Health Sciences, Section of Dermatology, University of Florence, Florence, Italy.
Scandagli I; Department of Health Sciences, Section of Dermatology, University of Florence, Florence, Italy.
Fastame MT; Department of Health Sciences, Section of Dermatology, University of Florence, Florence, Italy.
Prignano F; Department of Health Sciences, Section of Dermatology, University of Florence, Florence, Italy.
Pokaż więcej
Źródło:
The Journal of dermatological treatment [J Dermatolog Treat] 2022 Jun; Vol. 33 (4), pp. 1983-1985. Date of Electronic Publication: 2022 Mar 23.
Typ publikacji:
Journal Article; Observational Study
MeSH Terms:
Adalimumab*/adverse effects
Adalimumab*/therapeutic use
Biosimilar Pharmaceuticals*/adverse effects
Biosimilar Pharmaceuticals*/therapeutic use
Etanercept*/adverse effects
Etanercept*/therapeutic use
Infliximab*/adverse effects
Infliximab*/therapeutic use
Psoriasis*/drug therapy
Tumor Necrosis Factor Inhibitors*/adverse effects
Tumor Necrosis Factor Inhibitors*/therapeutic use
Dermatologic Agents/adverse effects ; Dermatologic Agents/therapeutic use ; Humans ; Necrosis/chemically induced ; Necrosis/drug therapy ; Retrospective Studies ; Treatment Outcome ; Tumor Necrosis Factor-alpha/antagonists & inhibitors
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknieSzczegóły
Wyświetlanie 1-20 z 19027

Ta witryna wykorzystuje pliki cookies do przechowywania informacji na Twoim komputerze. Pliki cookies stosujemy w celu świadczenia usług na najwyższym poziomie, w tym w sposób dostosowany do indywidualnych potrzeb. Korzystanie z witryny bez zmiany ustawień dotyczących cookies oznacza, że będą one zamieszczane w Twoim komputerze. W każdym momencie możesz dokonać zmiany ustawień dotyczących cookies